Skip to main content

Table 3 Decrease of RF titers in adalimumab treated patients: correlation with the clinical response to treatment

From: Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study

ACR response, week 24 Week 0 Week 24 P ACR response, week 48 Week 0 Week 48 P
<20% (n = 6) 130.5 ± 97.9 116.5 ± 88.6 n.s. <20% (n = 3) 89 ± 73 60.3 ± 49.2 n.d.
ACR 20 (n = 22) 155.3 ± 147.5 109 ± 123 <0.0001 ACR 20 (n = 23) 164.5 ± 141.3 105.7 ± 112.6 <0.0001
ACR 50 (n = 21) 94.1 ± 60.9 57.3 ± 36.2 <0.0001 ACR 50 (n = 16) 96.4 ± 73.2 51.6 ± 41 0.0001
ACR 70 (n = 8) 94.8 ± 164.2 40.4 ± 54 n.s. ACR 70 (n = 15) 89.5 ± 123.4 37.5 ± 40.7 0.018
  1. Results are means ± SD. ACR, American College of Rheumatology; n.d., not done; n.s., not significant; RF, rheumatoid factor.